Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 214-507-1 | CAS number: 1137-42-4
Carcinogenicity
Administrative data
Description of key information
Read-across data captured from published Benzophenone registration dossier:
Oral rats and mice 2y (OECD Guideline 451): There was some evidence of carcinogenic activity of benzophenone in male rats based on increased incidences of renal tubule adenoma.
These neoplasms were accompanied by significantly increased incidences of renal tubule hyperplasia and are likely a consequence of chronic injury.
Mononuclear cell leukaemia in male rats was increased in the low and mid dose compared to the control group, but due to the lacking dose response a relation to treatment is considered unlikely by the registrant. There was equivocal evidence of carcinogenic activity of benzophenone in female rats based on the marginally increased incidences of mononuclear cell leukaemia, also lacking a dose response relationship, and histiocytic sarcoma.
Tumor incidencies
Males:
Kidney: renal tubule, adenoma (standard evaluation - 1/50, 1/50, 2/50,
4/50; standard and extended evaluations combined - 2/50, 2/50, 7/50,
8/50)
Equivocal findings: Mononuclear cell leukaemia: (27/50, 41/50, 39/50,
24/50)
Females:
Equivocal findings: Mononuclear cell leukaemia: (19/50, 25/50, 30/50,
29/50); Histiocytic sarcoma: (0/50, 0/50, 1/50, 2/50)
Decreased incidences: Mammary gland: fibroadenoma (27/50, 24/50, 15/50,
7/50)
(Unnamed study report, 2006).
Statement from IARC: sufficient (but no clear) evidence for the carcinogenicity in experimental animals and possibly carcinogenic to humans. As stated the mechanistic evidence for the tumour induction by BP is weak.
Key value for chemical safety assessment
Justification for classification or non-classification
Classification, Labelling, and Packaging Regulation (EC) No 1272/2008
The available experimental test data are reliable and suitable for classification purposes under Regulation (EC) No 1272/2008, as amended for the seventh time in Regulation (EC) No 2015/1221. As a result the substance is considered to be not classified as carcinogen.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
